Pensionfund Sabic Lowers stake in United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : Pensionfund Sabic reduced its stake in United Therapeutics Corporation by 24.44% during the most recent quarter end. The investment management company now holds a total of 10,200 shares of United Therapeutics Corporation which is valued at $1.1 Million after selling 3,300 shares in United Therapeutics Corporation according to a report filed by the company on Apr 4, 2016 with the SEC.United Therapeutics Corporation makes up approximately 0.34% of Pensionfund Sabic’s portfolio.

Other Hedge Funds, Including , Pensionfund Dsm Netherlands reduced its stake in UTHR by selling 5,000 shares or 17.86% in the most recent quarter. The Hedge Fund company now holds 23,000 shares of UTHR which is valued at $2.5 Million. United Therapeutics Corporation makes up approx 0.34% of Pensionfund Dsm Netherlands’s portfolio.

On the company’s financial health, United Therapeutics Corporation reported $3.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.87 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $2.81. The company had revenue of $404.90 million for the quarter, compared to analysts expectations of $385.51 million. The company’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.21 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Sector Perform” and Lowered the Price Target to $ 122 from a previous price target of $150 .Shares were Reiterated by Wedbush on Mar 28, 2016 to “Outperform” and Lowered the Price Target to $ 229 from a previous price target of $238 .Shares were Reiterated by Wedbush on Mar 2, 2016 to “Outperform” and Lowered the Price Target to $ 238 from a previous price target of $244 .

United Therapeutics Corporation closed down -3.13 points or -2.77% at $109.81 with 7,73,177 shares getting traded on Monday. Post opening the session at $112.4, the shares hit an intraday low of $108.31 and an intraday high of $112.4 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.